Jubilant Pharmova Limited (JUBLPHARMA) AI Stock Analysis

• Market Cap: ₹156.22B
• Dividend Yield: 0.46%
• Average Volume (3M): 7.42K
• Price to Earnings (P/E): 32.5
• Beta (1Y): 1.32
• Revenue Growth: 10.09%
• EPS Growth: -19.40%
• Country: IN
• Employees: 5,399
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.85
• Shares Outstanding: 159,281,140
• 10 Day Avg. Volume: 4,911
• 30 Day Avg. Volume: 7,424
• PEG Ratio: 0.02
• Price to Book (P/B): 2.33
• Price to Sales (P/S): 2.01
• P/FCF Ratio: -334.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹1,040.00 ▼(-1.52% Downside)

Jubilant Pharmova Limited's stock score is primarily influenced by solid financial performance, with notable revenue growth and operational efficiencies. However, cash flow challenges and a high P/E ratio weigh down the score. Technical indicators suggest a neutral to slightly bullish trend, but valuation concerns limit the overall attractiveness of the stock.

Positive Factors

Diversified Business Model

Jubilant Pharmova’s multi-segment model (CDMO, radiopharma, allergy, generics) spreads revenue across specialized and commoditized areas. This reduces dependence on any single market, supports recurring manufacturing contracts in CDMO, and improves resilience to cyclical demand swings over months-to-years.

Balance Sheet Health

Manageable leverage and a near-50% equity base give the company financial flexibility to fund R&D, capex for specialized manufacturing, and regulatory compliance. A stronger ROE indicates improved capital efficiency, supporting sustainable investment in long-term CDMO and radiopharma capabilities.

Improving Operational Margins and Revenue Growth

Sustained revenue growth with expanding gross and EBIT margins signals lasting operational improvements and potential pricing or mix benefits from higher-value segments. If maintained, these trends strengthen cash generation capacity and support reinvestment into specialty manufacturing and R&D.

Negative Factors

Negative Free Cash Flow

High capex driving negative free cash flow erodes liquidity despite solid operating cash generation. Over 2–6 months this can constrain funding for working capital, delay strategic investments, or necessitate external financing, which increases financial risk and may pressure shareholder returns.

Low Net Profit Margin

A sub-12% net margin limits retained earnings and ROIC, reflecting mix exposure to lower-margin generics and cost pressures. Persistently thin margins reduce the buffer against pricing competition and regulatory compliance costs, weakening long-term ability to convert revenue into durable shareholder value.

Declining EPS

A near-20% decline in EPS signals deteriorating per-share profitability. If this persists it undermines reinvestment capacity, dividend potential, and market credibility. It may reflect mix, cost or one-off issues, but sustained EPS declines are a durable red flag for profit trajectory and capital allocation.

Jubilant Pharmova Limited Business Overview & Revenue Model

Company Description

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

How the Company Makes Money

Jubilant Pharmova generates revenue through multiple streams, including the sale of generic pharmaceuticals, branded formulations, and radiopharmaceuticals, which are used in diagnostics and treatment. The company also earns income from its contract manufacturing and development services, providing tailored solutions for other pharmaceutical companies. Key revenue streams include partnerships with healthcare providers and institutions, licensing agreements for proprietary formulations, and collaborations with global pharmaceutical companies. Additionally, Jubilant Pharmova benefits from its extensive distribution network and strategic alliances that enhance its market presence and drive sales growth.

Jubilant Pharmova Limited Financial Statement Overview

Summary

Jubilant Pharmova Limited shows solid revenue growth and improved operational efficiencies, as evidenced by enhanced gross and EBIT margins. The balance sheet reflects financial stability with manageable leverage. However, cash flow challenges, particularly negative free cash flow, are a concern that needs addressing for sustained growth.

Income Statement

Jubilant Pharmova Limited showed significant improvement in its gross profit and EBIT margins in the latest year, indicating enhanced operational efficiency. The revenue growth rate was robust at 8.86% year-on-year, suggesting positive momentum. However, the net profit margin remained relatively low at 11.60%, highlighting challenges in converting revenue to net income. The overall income statement reflects a healthy but uneven profit trajectory.

Balance Sheet

The balance sheet of Jubilant Pharmova Limited reveals a stable financial position with a debt-to-equity ratio of 0.44, indicating manageable leverage. The equity ratio stood at 49.02%, showing a strong equity base relative to total assets. Return on equity improved to 13.42%, reflecting enhanced shareholder returns. The balance sheet portrays financial stability with a moderate risk profile.

Cash Flow

Despite a strong operating cash flow, the company experienced a decline in free cash flow due to high capital expenditures, resulting in negative free cash flow. The free cash flow to net income ratio is unfavorable, signaling cash management challenges. However, the operating cash flow to net income ratio is solid at 1.28, indicating effective cash generation from operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	74.03B	72.34B	67.03B	62.82B	61.30B	60.99B
Gross Profit	48.11B	46.99B	43.52B	42.00B	46.42B	45.63B
EBITDA	11.46B	10.48B	7.93B	6.46B	10.66B	14.68B
Net Income	4.60B	8.39B	771.00M	-610.00M	4.14B	8.36B
Balance Sheet
Total Assets	0.00	127.56B	115.48B	111.57B	99.91B	89.18B
Cash, Cash Equivalents and Short-Term Investments	10.89B	10.89B	9.56B	10.15B	9.86B	6.89B
Total Debt	0.00	27.31B	36.64B	36.77B	31.92B	28.30B
Total Liabilities	-62.39B	65.18B	61.27B	57.65B	46.74B	41.77B
Stockholders Equity	62.39B	62.55B	54.34B	53.99B	53.19B	47.41B
Cash Flow
Free Cash Flow	0.00	-435.00M	736.00M	-1.54B	2.38B	12.57B
Operating Cash Flow	0.00	10.72B	9.71B	6.61B	8.38B	17.84B
Investing Cash Flow	0.00	4.88B	-6.08B	-5.44B	-3.80B	-7.39B
Financing Cash Flow	0.00	-14.53B	-4.33B	-1.57B	-325.99M	-17.09B

Jubilant Pharmova Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1056.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLPHARMA, the sentiment is Negative. The current price of 1056.1 is above the 20-day moving average (MA) of 1011.07, above the 50-day MA of 1048.40, and below the 200-day MA of 1079.40, indicating a bearish trend. The MACD of -31.41 indicates Positive momentum. The RSI at 43.86 is Neutral, neither overbought nor oversold. The STOCH value of 37.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLPHARMA.

Jubilant Pharmova Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹149.64B	9.72	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹138.45B	25.38	―	0.24%	8.14%	5.18%
CAPLIPOINT	69 Neutral	₹135.13B	22.95	―	0.31%	11.41%	19.22%
NEULANDLAB	67 Neutral	₹169.90B	70.75	―	0.08%	0.34%	-14.13%
JUBLPHARMA	62 Neutral	₹156.22B	32.52	―	0.46%	10.09%	-19.40%
APLLTD	60 Neutral	₹153.63B	24.22	―	1.28%	11.42%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jubilant Pharmova Limited Corporate Events

Jubilant Pharmova Creates Canadian Arm to Build Branded Generics Business

Jubilant Pharmova’s step-down subsidiary, Jubilant Generics Limited, has invested CAD 30,000 (about INR 0.20 crore) in Jubilant Pharmaceuticals Inc., a newly incorporated Canadian entity that will operate in the pharmaceuticals industry and is yet to commence business operations. With this initial cash investment, Jubilant Pharmaceuticals Inc. becomes a step-down wholly owned subsidiary, providing the group a direct platform to build a branded generics business in Canada, strengthen its presence in the Canadian market, and support future revenue growth without requiring additional regulatory approvals for the acquisition.

Jubilant Pharmova Subsidiary to Appeal Rs 9.71 Crore GST Demand, Sees No Material Impact

Jubilant Pharmova has disclosed that its wholly owned subsidiary, Jubilant Biosys Limited, has received an order from the Joint Commissioner of GST in Noida confirming a Goods and Services Tax demand of Rs 6.98 crore and a penalty of Rs 2.72 crore for the financial years 2020-21 to 2022-23, arising from alleged discrepancies in input tax credit claims. The company contends that the demand is legally untenable and based on frivolous grounds despite prior submission of documents, and it plans to challenge the order before the Commissioner (Appeals); management maintains that the case has strong merits, and asserts there will be no material impact on the group’s financials, operations or other activities, suggesting limited immediate risk for shareholders and other stakeholders.

Jubilant Pharmova’s Subsidiary to Contest GST Adjudication Order

Jubilant Pharmova Limited has announced that its wholly owned subsidiary, Jubilant Biosys Limited, received an Adjudication Order from the Deputy Commissioner of Commercial Taxes, Mysuru, concerning a demand for GST, interest, and penalty for the financial year 2021-2022. The company plans to file an appeal against the order, arguing that it is legally incorrect and expects no financial or operational impact from the order.

Jubilant Pharmova Appoints New CEO to Lead Therapeutics Subsidiary

Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the CEO of its subsidiary, Jubilant Therapeutics Inc. O’Connor brings over 30 years of experience in biotechnology and oncology, having previously increased company valuations and led successful acquisitions. His leadership is expected to advance Jubilant’s mission to develop innovative cancer therapies, potentially impacting stakeholders positively by driving breakthrough innovations in difficult-to-treat cancers.

Jubilant Pharmova Launches ‘Saksham Niveshak’ Campaign for Shareholders

Jubilant Pharmova Limited has launched the ‘Saksham Niveshak’ campaign, a 100-day initiative aimed at reminding shareholders about unpaid or unclaimed dividends. This campaign signifies the company’s proactive approach in engaging with its shareholders and ensuring that they receive their due entitlements, potentially strengthening shareholder relations and trust.

Jubilant Pharmova Releases Financial Results for Q2 2025

Jubilant Pharmova Limited has announced the publication of its unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2025. These results, approved by the Board of Directors, are accessible to investors through newspaper publications and the company’s website, reflecting the company’s commitment to transparency and regulatory compliance.